Vion Pharmaceuticals Proceeding To Second Stage Of Pivotal Phase II Trial Of Cloretazine(R) (VNP40101M) In Elderly AML

... VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it will proceed to the second stage of accrual to its pivotal Phase II trial of Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML). Vion Pharmaceuticals' trial CLI-043 is being conducted in over twenty North American and European sites. [click link for full article] ...